Management of cancer-related anemia: Epoetin alfa and quality of life

Seminars in Hematology

Volumn 37, Issue 4 SUPPL. 6, 2000, Pages 9-13

  Soignet, Steven ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; HEMOGLOBIN; IRINOTECAN; PACLITAXEL; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; TENIPOSIDE; TOPOTECAN; VINCRISTINE;

ANEMIA; BLOOD TRANSFUSION; CANCER; CONFERENCE PAPER; DISEASE SEVERITY; HEMOGLOBIN DETERMINATION; HUMAN; MORBIDITY; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0033786534     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/shem.2000.18118     Document Type: Conference Paper

References (16)

1. Quality of life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study
2. Implications of the anemia of chronic disorders in patients anticipating radiotherapy
3. Anemia of cancer
4. Anemia in cancer patients
5. Decreased erythropoietin response in patients with anemia of cancer
6. Chemotherapy-induced anemia in adults: Incidence and treatment
7. Collection and transfusion of blood and blood components in the United States, 1989
8. Prospective evaluation of transfusion requirements in anemic cancer patients +/- chemotherapy
9. Clinical guidelines for the treatment of cancer-related anemia
10. Erythropoietin for anemia in cancer patients
11. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy
12. Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin
13. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice
14. Once-weekly dosing of epoetin alfa is similar to three-times-weekly dosing in increasing hemoglobin and quality of life
15. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system
16. Identifying hemoglobin level for optimal quality of life: Results of an incremental analysis